医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Enhancing diagnostic accuracy:Role of stomach-specific serum biomarkers in real-world risk-based sequential screening for malignant gastric lesions

摘要Objective:A risk-based sequential screening strategy,from questionnaire-based assessment to biomarker measurement and then to endoscopic examination,has the potential to enhance gastric cancer(GC)screening efficiency.We aimed to evaluate the ability of five common stomach-specific serum biomarkers to further enrich high-risk individuals for GC in the questionnaire-identified high-risk population.Methods:This study was conducted based on a risk-based screening program in Ningxia Hui Autonomous Region,China.We first performed questionnaire assessment involving 23,381 individuals(7,042 outpatients and 16,339 individuals from the community),and those assessed as"high-risk"were then invited to participate in serological assays and endoscopic examinations.The serological biomarker model was derived based on logistic regression,with predictors selected via the Akaike information criterion.Model performance was evaluated by the area under the receiver operating characteristic curve(AUC).Results:A total of 2,011 participants were ultimately included for analysis.The final serological biomarker model had three predictors,comprising pepsinogen Ⅰ(PGI),pepsinogen Ⅰ/Ⅱ ratio(PGR),and anti-Helicobacter pylori immunoglobulin G(anti-H.pylori IgG)antibodies.This model generated an AUC of 0.733(95% confidence interval:0.655-0.812)and demonstrated the best discriminative ability compared with previously developed serological biomarker models.As the risk cut-off value of our model rose,the detection rate increased and the number of endoscopies needed to detect one case decreased.Conclusions:PGI,PGR,and anti-H.pylori IgG could be jointly used to further enrich high-risk individuals for GC among those selected by questionnaire assessment,providing insight for the development of a multi-stage risk-based sequential strategy for GC screening.

更多
广告
作者 Yanna Chi [1] Hongrui Tian [1] Chao Shi [2] Zhen Liu [1] Xue Li [3] Miao Zhang [4] Jun Liu [3] Xianmei Chen [3] Wenlei Yang [1] Yaqi Pan [1] Huanyu Chen [1] Mengfei Liu [1] Shengjuan Hu [3] Zhonghu He [5] Yang Ke [5] 学术成果认领
作者单位 Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Genetics,Peking University Cancer Hospital & Institute,Beijing 100142,China [1] Ningxia Clinical Research Institute,People's Hospital of Ningxia Hui Autonomous Region,Ningxia Medical University,Yinchuan 750001,China [2] Department of Gastroenterology,Endoscopic Center,People's Hospital of Ningxia Hui Autonomous Region,Ningxia Medical University,Yinchuan 750001,China [3] Department of Pathology,People's Hospital of Ningxia Hui Autonomous Region,Ningxia Medical University,Yinchuan 750001,China [4] State Key Laboratory of Molecular Oncology,Beijing Key Laboratory of Carcinogenesis and Translational Research,Department of Genetics,Peking University Cancer Hospital & Institute,Beijing 100142,China [5]
栏目名称
DOI 10.21147/j.issn.1000-9604.2025.02.03
发布时间 2025-06-16(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览5
  • 下载0
中国癌症研究(英文版)

中国癌症研究(英文版)

2025年37卷2期

154-164页

SCIMEDLINEISTICCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷